source
- ARCH Venture Partners aims to raise $3 billion for its 14th biotech fundARCH Venture Partners, a leading biotech venture capital firm, announced its intention to raise about $3 billion for a new fund. The proposed fund would be the firm's 14th and would rank among the…
- Alumis' TYK2 lupus drug fails mid-stage trial, CEO says clear path forwardAlumis announced that its TYK2 inhibitor did not meet primary endpoints in a mid-stage study in patients with lupus. The trial, which was the company's lead program, was designed to evaluate effic…